INTRODUCTION
The AP-2 family of developmentally regulated transcription factors consists of five members, AP-2α-ε, [1] [2] [3] [4] that are expressed during vertebrate embryogenesis in overlapping but distinct patterns of expression, especially within tissues undergoing morphogenesis [1] . The importance of these expression patterns has been borne out by homologous gene inactivation studies in mice. Mice lacking AP-2α showed multiple defects in the development of neural crest-derived tissues such as the cranio-facial skeleton [5] [6] [7] and the outflow tract of the heart [8] . Loss of AP-2β led to failed terminal kidney differentiation [9] . In contrast, AP-2γ was shown to be absolutely required within the extra-embryonic lineages for early postimplantation development [10, 11] . The more recently described AP-2δ and AP-2ε genes are thought to play more specialised roles in embryo brain and CNS [3, 12] .
Expression of AP-2 proteins in normal adult tissues is much more restricted.
However, a large number of studies have clearly demonstrated expression of AP-2α and AP-2γ, in particular, in a variety of solid tumours, including breast cancer where transcriptional targets include ERBB2, oestrogen receptor (ERα), and p21 WAF1/CIP1 (reviewed [13] ). Expression of AP-2α in breast cancer has generally been associated with a favourable outcome. For example, we and others have found a direct correlation between AP-2α and expression of ERα and the cell cycle inhibitor p21 WAF1/CIP1 , coupled with a lower rate of proliferation [14, 15] . AP-2α staining was found to be highest in normal breast epithelia with a decline in levels in samples of DCIS and the lowest expression in cases of invasive cancer [14] . Reduced nuclear AP-2α staining has also been associated with more aggressive, high-grade breast tumours [16] andTFAP2A mRNA expression has been inversely correlated with tumour grade [17] . In summary, AP-2α expression in tumours has been associated with favourable prognostic markers which has led to the suggestion that this factor may be acting in a tumour suppressive role, in breast cancer and in other cancer types (reviewed [13] ).
In contrast, elevated tumour levels of AP-2γ have largely been correlated with an adverse phenotype and increased disease progression. High levels of AP-2γ were found in testicular cancer [18] , germ cell tumours [18, 19] , advanced stages of ovarian cancer [20] and certain stages of melanoma [21] . In breast cancer, data mining of microarray expression studies has shown an association between high levels of TFAP2C mRNA and higher clinical grade and shorter survival times [17, 22] .
However, as reviewed recently [13] , the few studies that examined protein levels in breast cancer rarely used specific immunological reagents against AP-2γ, leading to apparently conflicting observations and a lack of clarity as to its overall role. In the current exploratory study, therefore, we have developed and carefully characterised a monoclonal antibody against AP-2γ and used it to examine expression levels in a series of primary invasive breast tumour samples (previously assayed for AP-2α [14] )
to determine if AP-2γ correlates with outcome. We have then further explored the relationship between AP-2γ endocrine response using breast cancer models.
METHODS

Cell lines
Acquired tamoxifen-resistant derivatives of MCF-7 (TamR) and T47D (T47D-R),
MCF-7 cells with acquired resistance to faslodex (FASR-LT) or to severe oestrogen and growth factor deprivation (MCF-7X) [23] [24] [25] [26] were examined in vitro.
Hormonal manipulation was carried out by supplementing standard growth medium (phenol-red-free RPMI medium containing 5% charcoal-stripped foetal calf serum, 200mM glutamine,10 IU/ml penicillin, 10ug/ml streptomycin) with either 10 -8
β-oestradiol, 10 -6 M 4-hydroxytamoxifen or 10 -7 M faslodex for 48 hours prior to cell harvest. Log-phase MCF-7, T47D, ZR75-1, MDAMB453 and MDAMB436 were also prepared for assay optimisation. For immunocytochemistry, cells were concentrated by centrifugation, transferred to 2% low melting point agarose/PBS at 37 o C to form solid pellets, fixed in 4% formal saline and embedded in paraffin wax. Pellets were cored and assembled in replicates using a tissue arrayer forming a composite array which was sectioned at 5μM for immunostaining.
Generation of AP-2γ monoclonal antibody, 6E4
A 30 kDa AP-2α/γ fusion protein (see Figure 1A ) was expressed in bacteria and purified [27] . Balb/c mice received four subcutaneous injections of purified protein (25μg/injecton) with adjuvant at four weekly intervals.
Electromobility shift assays (EMSA) and Western blotting
AP-2 proteins, synthesized in vitro (T'N'T kit; Promega) from wild-type and mutant AP-2 clones [28] , were used in EMSA assays as previously described [29] . used to construct an AP-2γ histopathology score (HScore; range 1-300) for each tumour specimen as detailed previously [31] , with epithelial staining also examined in DCIS and normal breast sections.
Mann-Whitney U-test was used to compare AP-2γ levels in comedo versus noncomedo DCIS and to examine tumour AP-2γ staining in relation to ER or ErbB2 status, response quality, menopausal status, disease site (locally-advanced vs. metastatic disease), tumour grade (1/2 vs. 3), PR and AP-2α/β status [14] .
Univariate analysis was performed using the Kaplan-Meier method with a log rank test . Multivariate analysis was performed using Cox's Proportional Hazards model, controlling for co-variates as listed in the Results. Univariate and multivariate analysis addressed AP-2γ impact on survival from initiation of therapy or on duration of therapeutic response, before and after subdivision for (i) ER or
(ii) ErbB2 status. p<0.05 was considered significant (*). No adjustments for multiple testing were made due to the exploratory nature of the study.
Results
Characterisation of AP-2γ monoclonal antibody
A bacterially expressed AP-2α/γ fusion protein ( Figure 1A Tumour epithelial staining was heterogeneous and entirely confined to the nuclei:
no cytoplasmic immunostaining was apparent and surrounding stromal cells and blood vessels were negative (see Figure 2A) . A proportion of the samples contained adjacent regions of tumour-associated DCIS (TAD; n = 19; see Figure   2B ) and/or tumour-associated normal epithelium (TAN; n= 32) which were also positive for AP-2γ expression. To examine these staining patterns further, we stained twenty cases of pure DCIS (10 comedo, 10 non-comedo) and saw higher AP-2γ staining (p = 0.015*) in the comedo (Median HScore = 95, range = 40-170; Figure 2C ) compared to the non-comedo samples (Median HScore = 23.5, range = 2-125; Figure 2D ). Notably, the former group were enriched for ErbB2 (50% overexpressors) relative to their non-comedo counterparts (no overexpressors).
Twenty samples of normal breast tissue from reduction mammoplasty patients were also examined. Staining was again nuclearand heterogeneous with apparently a higher proportion of intensely staining cells than seen in invasive tumours or DCIS ( Figure 3) ; this was particularly prominent and more homogeneous in the myoepithelium (see inset, Figure 3 ).
Elevated AP-2γ expression is associated with reduced patient survival
Examination of AP-2γ expression levels in this tumour series revealed a correlation between elevated AP-2γ and shortened survival from initiation of therapy (Table I) . We found a median survival of 39 months for cases with low AP-2γ as compared to 15 months for those with high AP-2γ expression (p=0.0009*). This is illustrated in Figure 4 , where a marked separation in survival curves is evident after 20 months. Clinically, patients are now stratified according to ER and ErbB2 status; we thus examined AP-2γ in the ER positive and the ErbB2 negative patient sub-groups, noting a significant relationship between higher expression and shortened survival in both (Table I) . These relationships in this patient series are intriguing given that ER positivity and ERBB2 negativity are generally considered as favourable prognostic indicators in breast cancer and suggest that nuclear AP-2γ positivity may be a marker of poorer outlook in this heterogeneous disease.
We also observed increased AP-2γ associated with shortened time to progression (TTP; 3 versus 9 months for AP-2γ "negative"; p=0.04*). Ag PubMed ain, this relationship was significant in ErbB2 negative patients (3 versus 10 months for AP-2γ high and low expressors respectively; p=0.002*), where examination of response quality at 6 months alsorevealed responders had lower AP-2γ than progressors (median HScore=95 and 135 respectively; p=0.013*).
Survival and TTP on anti-hormone therapy were additionally examined by multivariate analysis using Cox proportional hazards model. In addition to AP-2γ, co-variates considered for inclusion were ER, PR and ErbB2 status, site, grade and menopausal status. Univariate analysis revealed parameters significantly associated with survival in the series were grade (p=0.003), site (p<0.001) and ER status (p<0.001). These parameters were also significant in relation to TTP (p<0.001, p<0.001 and p<0.001 respectively) but additional factors were menopausal (p=0.005) and PR status (p=0.017). ErbB2 was not significant in either analysis. Significant co-variates were subsequently used to build survival and TTP models in multivariate analysis (Table II) . AP-2γ was an independent predictor of poorer survival, (p=0.005*) and also of decreased duration of response on anti-hormone therapy (p=0.046*). The association between increased hazard ratio and AP-2γ was retained in ErbB2 negative disease for survival (p=0.002*) and duration of response (p=0.002*). In ER positive patients, AP-2γ again related to reduced survival (p=0.048*), although associations with TTP were lost in this small series.
AP-2γ expression in in vitro models is associated with anti-hormone resistance TFAP2C has been shown to be a modestly oestrogen-responsive gene [33] . To explore the relationship further between AP-2γ levels and response versus resistance Localisation of AP-2γ in in vitro models of anti-hormone resistance was also investigated by immunostaining paraffin-embedded pellet arrays. As shown in Figure   6 , hormonally manipulated MCF-7 and also T47D cells expressed varying levels of AP-2γ but in all cases the protein remained predominantly nuclear. While 17β-estradiol was stimulatory, acute addition of tamoxifen again reduced AP-2γ staining in MCF-7 cells ( Figure 6 , compare panels A, B and C). However, cells which had become refractory to tamoxifen showed fully-restored wild-type levels of nuclear AP-2γ that were again maintained when these cells were exposed to faslodex ( Figure 6 , compare Panels D, E with A). T47D cells extensively cultured in tamoxifen also expressed wild-type levels of AP-2γ ( Figure 6 , panels H and I). Moreover, the MCF-7X model (resistant to severe oestrogen deprivation) and acquired faslodex resistant cells also displayed readily-detectable levels of nuclear AP-2γ, with particularly substantial levels in the former ( Figure 6 , compare panels F, G and A).
Thus, while AP-2γ levels clearly fall during tamoxifen response, these experimental models demonstrate that breast cancer cells re-instigate substantial levels of nuclear (and therefore potentially active) AP-2γ when they become anti-hormone resistant.
Together with our observational study associating higher AP-2γ levels with poorer outcome in anti-hormone treated patients, these data suggest a potential contribution for AP-2γ in the biology of diverse, anti-hormone-resistant states.
DISCUSSION
Studies examining expression of the AP-2γ transcription factor in tumours have often used reagents that are either poorly characterised or which recognise multiple AP-2 family members [13] . Here we describe the generation and extensive characterisation of a specific monoclonal antibody against AP-2γ and its application to examine factor expression levels in normal and malignant breast tissue. Strong AP-2γ staining was noted in the nuclei of both epithelial and myoepithelial cells of the pure normal breast samples, with a marked mosaic expression in normal luminal epithelial cells (Figure 3 ), which reflects findings in the terminal end buds (TEBs) of the developing mouse mammary gland. TEBs ultimately form the ductal network and contain two cell populations: body cells which will form ductal epithelial tissue and cap cells which are the progenitors of the myoepithelial layer. A mosaic, rather than uniform, pattern of expression for AP-2γ was noted in both cell types in mouse TEBs [34] .
Compared to the level of staining in normal tissue, we see an apparent reduction in AP-2γ nuclear staining between normal epithelial cells and either DCIS or invasive tissue. Similar data was noted from microarray studies where AP-2γ was shown to be expressed at a significantly higher level in samples of normal tissue or benign disease than in cases of ductal carcinoma ( [22, 35] ; p= 0.002 and 0.009 respectively). Our most striking finding however, is that, for those patients whose tumours retained high levels of nuclear AP-2γ expression, there appears to be an association with reduced patient survival from initiation of therapy in this series ( Figure 4 ). This relationship is retained in ER positive and ErbB2 negative cases, two patient sub-groupings generally considered to have a relatively good prognosis in breast cancer. Since high levels of AP-2γ occur in normal breast epithelial cells, elevated expression of this factor per se is unlikely to be a tumour initiating event. However, our data imply a positiverole for this factor in facilitating adverse behaviour of cancers that arise in AP-2γ expressing epithelial cells. Thus, AP-2γ may prove to be a marker for patients with an otherwise favourable prognosis who fail to respond to therapy. In support of this, univariate and multivariate analyses indicated that AP-2γ status was an independent predictor of poor outcome, particularly for survival, but also for progression on anti-hormone therapy in this series.
Few previous reports have specifically examined AP-2γ expression in breast cancer but, in agreement with this study, a qPCR analysis of 38 primary breast tumours found a significant association between elevated TFAP2C mRNA and reduced disease-free survival, although an association with overall survival was not observed [36] . Two other studies using different polyclonal AP-2γ antibodies failed to find a link with outcome. One study focused on patients with early-stage disease treated with lumpectomy [15] and in the second study the commercial antibody employed apparently only stained the myoepithelial compartment [37] . In contrast, using gene expression profiling, TFAP2C mRNA expression was associated with advancing clinical grade (p<0.002, [17] ). It was also found to be significantly higher in patients who died within 5 years of breast cancer compared to those patients who were still disease free after 5 years ( [22] ; p=0.0177), while AP-2α mRNA expression levels were not significantly different between these two patient groups.
Our study further highlights the opposing roles seemingly played by the two AP-2 family members in breast cancer. AP-2 factors can regulate expression of the cell cycle inhibitor p21 WAF1/CIP1 and ERα [1, 13] and for AP-2α this relationship may underlie associations between elevated levels of this factor and an indolent breast cancer phenotype. In contrast, elevated AP-2γ expression has been shown here to be an independent predictor of poorer survival, where its expression did not relate to AP-2α/β status as previously determined for this series [14] . Interestingly, although mammary-directed overexpression of AP-2γ in transgenic mice did not lead to tumour development, marked epithelial hyperplasia was observed [38] implicating AP-2γ in the promotion of breast epithelial cell proliferation.
High levels of nuclear AP-2γ may also be associated with an anti-hormone resistant phenotype, as suggested by our clinical and in vitro findings and also supported by a recent study thatexamined AP-2γ levels within a series of ER+ patients with known response to tamoxifen. Multivariate analysis revealed AP-2γ to be an independent marker of resistance to tamoxifen, particularly in postmenopausal patients [39] .
Failure of, or resistance to, anti-hormone therapy remains a major problem in the clinical management of breast cancer and several mechanisms have been proposed to account for this resistance that can equate with poor prognosis [40] . As exemplified by our TamR models [23, 41] , essentially all of these mechanisms lead to the activation of alternative signalling pathways that bypass cell cycle arrest and allow cells to continue to proliferate and progress to more aggressive states. In ER+ patients, AP-2γ as a ligand-activated ERα target gene [33] would be expected to be down-regulated by tamoxifen. However, poor anti-hormone response in tumours with high nuclear AP-2γ might be associated with failed ERα regulation of TFAP2C Since only 75 patients were examined in this study, it must be deemed exploratory,
where future confirmatory studies in larger clinical breast cancer sets with associated endocrine response and survival data will be imperative. Nevertheless, the findings of the present study are clearly important since they suggest that AP-2γ expression may be an indicator of reduced patient survival in breast cancer and that this factor therefore plays an opposite role to that of AP-2α in this disease. AP-2γ expression may also equate with a lack of response to anti-hormonal therapy, as supported by our in vitro findings. 
TABLES
Additional information about the patient series (for on-line publication)
The study series is a historic, mixed patient group comprising:
(i) patients presenting with primary disease that was either locally-advanced (i.e. with large tumours >5cm) or metastatic who were treated with surgery immediately followed by endocrine therapy.
(ii) patients presenting with primary disease that, following surgical treatment alone, recurred with metastatic disease. These patients were then treated with endocrine therapy for this metastatic disease.
These samples have been used in many immunohistochemical studies to explore if there is a relationship between the clinical impact of first exposure to endocrine therapy (including survival measured from initiation of treatment) and the biomarker under test (in this instance AP-2γ) as measured in the primary tumour.
At the time of accumulation of this series (1984) (1985) (1986) (1987) , the prevailing view was that adjuvant endocrine therapy did not affect survival [1] and this did not become routine practice until the Oxford overview [2] , explaining why this study also includes patients initially treated with surgery only for their primary disease. During this period patients with ER negative disease were also considered for a trial period on endocrine therapy, as up to 10% response rates were occasionally observed. Thus, all patients in the study were treated with tamoxifen-based regimes, as determined by menopausal status (see article text). Since 90% of the ER-patients did not respond to endocrine therapy they may have been considered for chemotherapy once they progressed. However, there is no detailed log available for the chemotherapeutic regimens that might have been subsequently employed or indeed which, if any, ERpatients received such treatment. Moreover, since ErbB2 was not routinely measured at the time (this was examined later for this series as an exploratory marker), potential use of chemotherapy cannot be extrapolated from this status.
Further data were available for this series including patient age, menopausal status, disease site (locally advanced versus metastatic disease), tumour type and grade (nuclear pleomorphism, tubular differentiation, mitotic activity), PR and ER status (ER+ n=45; ER-n=30), as well as proliferative capacity (Ki67) and 
